Theralizumab, CAS 906068-56-2

Product Description: Theralizumab (TGN1412) is a humanized lgG4 superagonistic anti-CD28 monoclonal antibody that directly stimulates T cells. Theralizumab can cause cytokine release syndrome (CRS). Theralizumab can be used for the research of rheumatoid arthritis[1][2].

Applications: COVID-19-immunoregulation

Formula: N/A

References: [1]Thomas Hünig. The rise and fall of the CD28 superagonist TGN1412 and its return as TAB08: a personal account. FEBS J. 2016 Sep;283(18):3325-34./[2]Dmitry Tyrsin, et al. From TGN1412 to TAB08: the return of CD28 superagonist therapy to clinical development for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. Jul-Aug 2016;34(4 Suppl 98):45-8./[3]Weißmüller S, et al. TGN1412 Induces Lymphopenia and Human Cytokine Release in a Humanized Mouse Model. PLoS One. 2016 Mar 9;11(3):e0149093./[4]Hussain K, et al. Upregulation of FcγRIIb on monocytes is necessary to promote the superagonist activity of TGN1412. Blood. 2015 Jan 1;125(1):102-10.

CAS Number: 906068-56-2

Molecular Weight: N/A

Compound Purity: 97.21

Research Area: Inflammation/Immunology

Solubility: H2O

Target: CD28

• Artikelnummer: MEXHY-P9975-1
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P9975-1
• Verpackungseinheit: 1 mg
• Mengeneinheit: STK
• Konjugat: Unconjugated